Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial) (DEPTH)

  • End date
    Jun 19, 2024
  • participants needed
  • sponsor
    Weill Medical College of Cornell University
Updated on 7 October 2022
cigarette smoke


The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV.

The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of antibiotic-resistant bacterial infections.


This study is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial in approximately 250 people living with HIV who have emphysema.

Eligible participants will be randomized in a 1:1 fashion to doxycycline or placebo. Participants will receive 100 mg doxycycline orally or matched placebo twice a day for 72 weeks.

Condition Emphysema, HIV
Treatment Placebo, doxycycline
Clinical Study IdentifierNCT05382208
SponsorWeill Medical College of Cornell University
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Male or female age 30 years and older at screening visit
HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to the enrollment visit, and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load
Current or former smoker with at least a 3 pack-year history of cigarette smoking at screening visit
Evidence of emphysema on high resolution CT (HRCT) of the chest done at pre-entry visit. Emphysema is defined as 5 to 35% of voxels with density < -950 Hounsfield Units (HU)
Low DLCO, defined as < LLN by the Global Lung Initiative (GLI) predicted set for DLCO adjusted for barometric pressure, hemoglobin and carboxyhemoglobin based on the mean of screening and pre-entry measurements
HIV-1 RNA level < 200 copies/ml within 90 days prior to the Entry/Baseline visit by any US laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent
CD4 cell count > 200 cells/mm3 within 90 days prior to the Entry/Baseline any US laboratory that has a CLIA certification or its equivalent
Stable antiretroviral therapy for greater than or equal to 8 weeks prior to the Entry/Baseline visit. Substitutions of one formulation of a drug for another are not considered changes in antiretroviral therapy for the purpose of defining stable therapy
Calculated creatinine clearance (CrCl) greater than or equal to 60 mL/min as estimated by the Cockcroft-Gault equation within 45 days prior to the Entry/Baseline visit
Serum ALT and AST < 3 x upper limit of normal within 45 days prior to the Entry/Baseline visit
Participants on therapy for COPD must be on stable therapy for at least 4 weeks prior to the Entry/Baseline visit
Documentation of serum alpha-1-antitrypsin level above the lower limit of normal from a test done at any time prior to the Entry/Baseline visit
Provision of signed and dated written informed consent
Stated willingness to adhere to all study procedures and anticipated availability for the duration of the study
Life expectancy > 2 years in the opinion of the site investigator
Ability to take oral medication and willingness to adhere to the study drug
For individuals of reproductive potential, negative serum or urine pregnancy test with a sensitivity of less than or equal to 25 mIU/mL at the screening visit. This will be repeated at the Entry/Baseline visit

Exclusion Criteria

Pulmonary infection, acute COPD exacerbation, acute opportunistic infection within 30 days prior to the Entry/Baseline visit
Any acute or serious illness requiring systemic treatment and/or hospitalization within 30 days prior to the Entry/Baseline visit
Decompensated cirrhosis defined as an acute deterioration in liver function in a patient with cirrhosis and is characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome or variceal hemorrhage
History of, or planned, wedge resection, lobectomy, pneumonectomy, or lung volume reduction surgery
History of, or planned, endobronchial valve placement for lung volume reduction
Significant parenchymal lung disease other than emphysema or chronic bronchitis (e.g. sarcoidosis, MAI infection, pulmonary fibrosis, lung cancer)
Previous allergy or intolerance to doxycycline or other drugs in the tetracycline class (e.g. minocycline, tetracycline)
Breastfeeding individuals
Receipt of any investigational drug within 30 days prior to the Entry/Baseline visit. Note: for the purpose of this protocol, investigational drug refers to a drug that is not FDA approved for any indication. COVID vaccines available under emergency use authorization are allowed
Need for concomitant use of barbiturates; carbamazepine; phenytoin
Use of systemic retinoids (eg. Isotretinoin [Accutane]) or Vitamin A within 30 days prior to the Entry/Baseline visit. Note: Multivitamin containing Vitamin A use is permitted
Use of any systemic antibiotic (e.g., doxycycline or other tetracycline, azithromycin) within 7 days prior to the Entry/Baseline visit
Any condition including active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
History of recurrent C. difficile infection or C. difficile infection within 30 days prior to the Entry/Baseline visit
History of Pneumocystis pneumonia
Inability to stop supplemental oxygen for 15 minutes to perform a DLCO maneuver
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note